BeiGene
BeiGene, Ltd. is a global biotechnology company founded in 2010, focused on discovering and developing innovative oncology treatments to improve accessibility and affordability for cancer patients worldwide. Headquartered in Beijing, the company operates in the U.S., China, and internationally, employing over 9,200 individuals and housing one of the largest oncology research teams globally. BeiGene's commercial products include BRUKINSA, a BTK inhibitor for blood cancers, and Tislelizumab, an anti-PD-1 antibody, which is under regulatory review in the U.S. and EU for advanced esophageal cancer. The company's extensive pipeline targets various malignancies, including acute myeloid leukemia, multiple myeloma, and solid tumors, with potential to address numerous cancer types. In addition to its product portfolio, BeiGene sponsors initiatives to support the broader needs of oncology patients, such as mental health awareness programs. The company has established collaborations with several biotechnology and pharmaceutical firms to enhance its research and development capabilities.
Duo Oncology is focused on developing innovative nanoparticle technology designed to effectively penetrate established tumors, particularly in challenging cases such as pancreatic and bile duct cancers. The company aims to transform treatment outcomes through a novel monotherapy that enhances patient care for those with hard-to-treat tumors and relapsed metastatic disease. By collaborating with leading university scientists and medical oncologists, Duo Oncology leverages a network of established research organizations to expedite the development of its products. The technology addresses significant needs in immunotherapy and precision medicine, ultimately striving to improve recovery times and patient outcomes.
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer.
Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.
Singlomics uses single-cell sequencing technology to develop antibody drugs for the treatment of infectious diseases and cancers.
Leap Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing targeted and immuno-oncology therapies for cancer treatment. Founded in 2011, the company primarily focuses on acquiring and advancing therapies that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1), currently undergoing clinical trials for various cancers, including esophagogastric, gynecologic, and colorectal cancers. Additionally, Leap Therapeutics is developing FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at creating transformative cancer treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.